Lung cancer Patients' own immune cells could be new weapon
NCT ID NCT06455917
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a therapy using a patient's own tumor-infiltrating lymphocytes (TILs) to treat advanced non-small cell lung cancer. Doctors collect immune cells from a tumor, grow them in a lab, and infuse them back after mild chemotherapy. The goal is to see if this slows cancer growth. The trial enrolls 30 adults who have already tried standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tumor-infiltrating lymphocytes (TILs)
What this could lead to
If successful, this could offer a new treatment option for advanced lung cancer patients who have run out of standard therapies.
What could go wrong
This is an early phase II trial with only 30 participants, so results may not apply broadly. The treatment involves intensive chemotherapy and carries risks like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Medical Oncology, University Hospital Basel
RECRUITINGBasel, Canton of Basel-City, 4031, Switzerland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact